<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683783</url>
  </required_header>
  <id_info>
    <org_study_id>PI19/256</org_study_id>
    <nct_id>NCT04683783</nct_id>
  </id_info>
  <brief_title>National Registry of Liver First Approach</brief_title>
  <acronym>RENACI</acronym>
  <official_title>RENACI Project: National Registry of Liver First Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociación Española de Cirujanos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Miguel Servet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver metastases are present in 15-25% of patients with colorectal cancer at the time of&#xD;
      diagnosis of the primary tumor, which is defined as synchronous liver metastases. Treatment&#xD;
      for the potential cure of this disease includes surgical resection of both the primary tumor&#xD;
      and liver metastases. The liver first approach was described by Mentha for patients with&#xD;
      asymptomatic rectal tumors with with initially unresectable or borderline resectable liver&#xD;
      metastases. There is little data in the scientific literature on how many patients scheduled&#xD;
      for this strategy complete both surgeries and/or undergo the full chemo/radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver metastases are present in 15-25% of patients with colorectal cancer at the time of&#xD;
      diagnosis of the primary tumor, which is defined as synchronous liver metastases. Treatment&#xD;
      for the potential cure of this disease includes surgical resection of both the primary tumor&#xD;
      and liver metastases. However, due to the comorbidity or extent of the tumor disease, only a&#xD;
      minority of patients are candidates for curative resections. When surgical treatment is&#xD;
      indicated, different strategies can be used. In the classic strategy, the primary tumor is&#xD;
      resected first, followed by surgery for metastases and, after that, adjuvant chemotherapy.&#xD;
      More recently, simultaneous resection of primary and liver lesions has been used, mainly for&#xD;
      limited liver disease without the need for large-volume liver resections. A third option is&#xD;
      preoperative chemotherapy, followed by resection of liver metastases and surgery of the&#xD;
      primary tumor in a second stage. This technique was initially described in 2006 by Mentha for&#xD;
      patients with asymptomatic rectal tumors with initially unresectable or borderline resectable&#xD;
      liver metastases. These patients were treated with neoadjuvant chemotherapy, followed by&#xD;
      surgery for liver metastases, chemo/radiotherapy of the primary tumor, and second stage&#xD;
      surgery. This is what is called surgery or reverse strategy (liver first approach in the&#xD;
      Anglo-Saxon world). This strategy has the potential advantage of allowing resection of&#xD;
      advanced liver disease in patients when the primary tumor is asymptomatic. Advanced liver&#xD;
      disease is the leading cause of mortality in these patients. Subsequently, this strategy has&#xD;
      been used in colorectal tumors of any location with synchronous metastases. No clear&#xD;
      advantage or disadvantage has been demonstrated with any of the three strategies in terms of&#xD;
      long-term survival. There is also no prospective randomized clinical trial comparing&#xD;
      classical with reverse strategy.&#xD;
&#xD;
      Most of the previous studies that evaluated this strategy only included patients with liver&#xD;
      resection, not the primary one. Therefore, there is little data in the scientific literature&#xD;
      on how many patients scheduled for this strategy complete both surgeries and/or undergo the&#xD;
      full chemo/radiation therapy. The potential advantage of this strategy is the possibility of&#xD;
      rescuing more patients with colorectal cancer liver metastases, thus increasing survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of patients who complete the entire cycle</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of patients who complete the cycle: neoadjuvant chemotherapy - liver surgery - CT / RT of the primary - surgery of the primary tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative mortality including liver surgery and primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative morbidity including liver surgery and primary tumor (all type of postoperative complications)</description>
  </secondary_outcome>
  <enrollment type="Actual">168</enrollment>
  <condition>Colonic Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients operated on in the participating Spanish centers with colorectal cancer and&#xD;
        synchronous liver metastases who underwent a liver first approach during the study period&#xD;
        and that meet the inclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 year old.&#xD;
&#xD;
          -  Scheduled surgery for colorectal cancer with synchronous liver metastases using the&#xD;
             liver first approach.&#xD;
&#xD;
          -  ASA score I-III.&#xD;
&#xD;
          -  They have signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 year old.&#xD;
&#xD;
          -  ASA ≥ IV.&#xD;
&#xD;
          -  Urgent surgery.&#xD;
&#xD;
          -  Patients who have not signed the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mario Serradilla Martín</name>
      <address>
        <city>Zaragoza</city>
        <zip>50008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013 Apr;148(4):385-91. doi: 10.1001/jamasurg.2013.1216. Review.</citation>
    <PMID>23715907</PMID>
  </results_reference>
  <results_reference>
    <citation>de Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, Dejong CH. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford). 2011 Oct;13(10):745-52. doi: 10.1111/j.1477-2574.2011.00372.x. Epub 2011 Sep 5.</citation>
    <PMID>21929676</PMID>
  </results_reference>
  <results_reference>
    <citation>Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford). 2014 Feb;16(2):101-8. doi: 10.1111/hpb.12083. Epub 2013 Mar 19. Review.</citation>
    <PMID>23509899</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsoulfas G, Pramateftakis MG. Management of rectal cancer and liver metastatic disease: which comes first? Int J Surg Oncol. 2012;2012:196908. doi: 10.1155/2012/196908. Epub 2012 Jun 20.</citation>
    <PMID>22778934</PMID>
  </results_reference>
  <results_reference>
    <citation>Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8.</citation>
    <PMID>16671066</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, Choti MA, Gindrat I, Aldrighetti L, Barrosso E, Mentha G, Pawlik TM. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg. 2013 Apr;216(4):707-16; discussion 716-8. doi: 10.1016/j.jamcollsurg.2012.12.029. Epub 2013 Feb 21.</citation>
    <PMID>23433970</PMID>
  </results_reference>
  <results_reference>
    <citation>Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E; Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225-39. doi: 10.1634/theoncologist.2012-0121. Epub 2012 Sep 7.</citation>
    <PMID>22962059</PMID>
  </results_reference>
  <results_reference>
    <citation>Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015 Nov;41(9):729-41. doi: 10.1016/j.ctrv.2015.06.006. Epub 2015 Jun 30. Review.</citation>
    <PMID>26417845</PMID>
  </results_reference>
  <results_reference>
    <citation>Ihnát P, Vávra P, Zonča P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go? World J Gastroenterol. 2015 Jun 14;21(22):7014-21. doi: 10.3748/wjg.v21.i22.7014. Review.</citation>
    <PMID>26078580</PMID>
  </results_reference>
  <results_reference>
    <citation>Waisberg J, Ivankovics IG. Liver-first approach of colorectal cancer with synchronous hepatic metastases: A reverse strategy. World J Hepatol. 2015 Jun 18;7(11):1444-9. doi: 10.4254/wjh.v7.i11.1444.</citation>
    <PMID>26085905</PMID>
  </results_reference>
  <results_reference>
    <citation>Sturesson C, Valdimarsson VT, Blomstrand E, Eriksson S, Nilsson JH, Syk I, Lindell G. Liver-first strategy for synchronous colorectal liver metastases - an intention-to-treat analysis. HPB (Oxford). 2017 Jan;19(1):52-58. doi: 10.1016/j.hpb.2016.10.005. Epub 2016 Nov 9.</citation>
    <PMID>27838252</PMID>
  </results_reference>
  <results_reference>
    <citation>Regimbeau JM, Cosse C, Kaiser G, Hubert C, Laurent C, Lapointe R, Isoniemi H, Adam R. Feasibility, safety and efficacy of two-stage hepatectomy for bilobar liver metastases of colorectal cancer: a LiverMetSurvey analysis. HPB (Oxford). 2017 May;19(5):396-405. doi: 10.1016/j.hpb.2017.01.008. Epub 2017 Mar 23.</citation>
    <PMID>28343889</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Miguel Servet</investigator_affiliation>
    <investigator_full_name>Mario Serradilla, MD, FACS</investigator_full_name>
    <investigator_title>MD, FACS</investigator_title>
  </responsible_party>
  <keyword>Liver first approach</keyword>
  <keyword>Reverse strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

